DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Friday morning. The firm issued a hold rating on the stock.

Several other research firms have also weighed in on DBVT. HC Wainwright lifted their target price on shares of DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a research note on Tuesday, September 24th.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $0.47 on Friday. The firm has a market capitalization of $45.62 million, a price-to-earnings ratio of -0.53 and a beta of 0.66. DBV Technologies has a one year low of $0.44 and a one year high of $2.14. The company’s 50 day moving average price is $0.70 and its 200 day moving average price is $0.86.

DBV Technologies’s stock is set to reverse split on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Institutional Trading of DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. boosted its position in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies makes up 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.